CytoMed Therapeutics (GDTC) Research & Development (2022 - 2025)
CytoMed Therapeutics (GDTC) posted Research & Development of $272848.0 for Q2 2025, up 175.61% sequentially from -$360871.0 in Q2 2024, and up 175.61% YoY from $98998.5 in Q2 2024.
CytoMed Therapeutics (GDTC) Research & Development (2022 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Research & Development for 4 years, with the latest figure at $272848.0 in Q2 2025.
- Quarterly Research & Development rose 175.61% year-over-year to $272848.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.8 million (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, up 23.38% from the prior year.
- Research & Development rose to $272848.0 in Q2 2025 per GDTC's latest filing, from -$360871.0 in the prior quarter.
- Over five years, Research & Development peaked at $1.3 million in Q2 2023 and troughed at -$360871.0 in Q2 2024.
- A 4-year average of $454637.8 and a median of $438445.5 in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 127.71% in 2024, then surged 175.61% in 2025.
- Over 4 years, Research & Development stood at $604043.0 in 2022, then jumped by 115.64% to $1.3 million in 2023, then tumbled by 127.71% to -$360871.0 in 2024, then soared by 175.61% to $272848.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $272848.0, -$360871.0, and $1.3 million for Q2 2025, Q2 2024, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 97.90 Mn |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 272,848.00 |
| Jun 30, 2024 | -360,871.00 |
| Jun 30, 2023 | 1.30 Mn |
| Jun 30, 2022 | 604,043.00 |